<DOC>
	<DOC>NCT02383680</DOC>
	<brief_summary>Travelers (n = 30, 15 taking low-dose methotrexate (MTX), 15 healthy controls (HC), seeking travel advice in one of the following Swiss Travel Centers (Aarau, Basel, Bern, Geneva, Lausanne, Zurich) and who have an indication for yellow fever (YF) vaccination according to the Swiss Federal Office of Public Health's vaccination recommendations are invited to participate in this study. After signing the consent form (i) YF viremia and (ii) anti-YF antibody production in patients taking low-dose MTX and HC will be compared after YF vaccination. It will be analyzed whether the percentage of people with protective antibodies differs between the two groups and (iii) vaccine side effects will be compared between the groups.</brief_summary>
	<brief_title>Yellow Fever Vaccination Under Low Dose Methotrexate Therapy</brief_title>
	<detailed_description>The study will be conducted in the form of a multi-center open-label prospective observational controlled pilot study. 15 patients under low dose methotrexate treatment and 15 healthy controls with an indication for yellow fever vaccination will be included. The study duration will be 28 days for each subject and will consist of 6 clinical visits on days 0, 3, 7, 10, 14 and 28. YF antibodies will be measured on days 0, 7, 10, 14 and 28; viremia will be measured on days 3, 7, 10, 14 and 28.</detailed_description>
	<mesh_term>Yellow Fever</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Informed Consent as documented by signature Indication for yellow fever vaccination according to Swiss FOPH recommendations Individuals under low dose MTX (≤20mg/week) therapy or healthy individuals Male and Female travelers ≥18 years to &lt;60 years of age Contraindications on ethical grounds Women who are pregnant or breast feeding Contraindication against yellow fever vaccination (e.g. hypersensitivity against vaccine ingredient) Current treatment with other immunosuppressive agent apart from low dose methotrexate Alemtuzumab or rituximab in the last year TNFblocking therapy in past three months Immunocompromising condition in healthy control Other immunocompromising condition than MTX treatment itself and the underlying disease in patients under MTX Previous yellow fever vaccination No indication for yellow fever vaccination according to Swiss travel vaccination recommendations Known or suspected noncompliance, drug or alcohol abuse Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Methotrexate therapy</keyword>
</DOC>